TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Apogee International

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements;~* Enrollment into Apogee International will be comprised of newly enrolled, commercial use patients with the HeartWare HVAD System;~* Patient is consented prior to the HVAD implant procedure.~Exclusion Criteria:~* Patient who is, or is expected to be inaccessible for follow-up;~* Participation is excluded by local law;~* Patient is currently enrolled or plans to enroll in concurrent drug/device study that may confound the PSR results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients implanted with HVAD System (Type: None): Patients intended to be implanted with a HeartWare HVAD per the current (local) guidelines, are eligible for enrollment into Apogee International and must be consented for Apogee International prior to the HVAD implant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years old~2. NK stage 2 or 3 (Mackie classification)~3. Signed Informed Consent Form~4. The patient is able to understand the nature of the study and to participate throughout its duration~Exclusion Criteria:~1. Medical history of eye tumors~2. Active eye infection~3. Eyelid bad position or eyelid closure problems~4. Conjunctiva scarring~5. Topic chronic eye treatments with corticoids~6. Acute corneal burns (\<3 months)~7. Intolerance to contact lens~8. Allergy or inability to receive concomitant treatment with Exocin®~9. Patients with immunosuppressive or chemotherapy treatment~10. Pregnant woman or woman without proper contraceptive methods according to the investigator (\*), or lactating women~11. Participation in another clinical trial in the last month (\*) Contraceptive methods accepted in the protocol are: hormonal, intrauterine device (IUD), barrier methods, voluntary sterilization or the patient has menopause \>1 year duration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cord blood eye drops (Type: EXPERIMENTAL): Experimental drug: cord blood eye drops Description: eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 19 vials of 1 mL per vial Route of administration: ophthalmic/ocular
- Conventional treatment (Type: ACTIVE_COMPARATOR): Conventional treatment:~1. Artificial tears Description: Lubristil ® (single dose) Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 20 or 30 vials of 0.3 mL per vial Route of administration: ophthalmic~2. Therapeutic Contact lens Description: Air Optix Night\&Day Dosage regimen: 1 contact lens per visit Pharmaceutical form: contact lens Presentation: 1 unit per case Route of administration: ophthalmic/ocular

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Erythropoietin in Premature Infants to Prevent Encephalopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Birthweight less or equal 1500 grams~2. Less than 32 weeks gestation at birth~3. Less than 48 hours of life at time of enrollment~4. Written informed consent of parent or guardian~Exclusion Criteria:~1. Intrauterine Growth Retardation~2. Severe Congenital Anomalies adversely affecting life expectancy or neurodevelopment~3. Genetic Metabolic Diseases~4. Seizures within first 24 hours of life~5. Severe neutropenia (ANC \< 500 cells/microL) within first 24 hours of life~6. Polycythemia (Hct \> 65%) within first 24 hours of life~7. Thrombocytopenia (platelets \< 50K cells/microL) within first 24 hours of life~8. Hypertension (SBP \> 100mmHg) without vasopressor support within first 24 hours of life~9. Microcephaly~10. Grade III-IV intracranial hemorrhage~Termination~1. Required by parent or guardian;~2. Polycythemia through blood transfusion can not be relieved~3. Oliguria（\<0.5mL/kg/h for at least 24 hours）~4. Progression of azotemia~5. Pulmonary hypertension or Cardiac arrhythmia

- Gender: ALL
- Minimum Age: None
- Maximum Age: 48 Hours
- Healthy Volunteers: f

Study Arms:
- Erythropoietin (Type: EXPERIMENTAL): Epo is administered 1000 U/kg, iv in 48 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
- Normal saline (Type: PLACEBO_COMPARATOR): Normal saline is administered 5ml, iv at 3 to 6 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Smart Phone Application in the Secondary Clinical Prevention Management for Chinese Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* First diagnosis of coronary heart disease and received a PCI treatment.~* Age 18-65 years.~* Able and willing to provide written informed consent.~Exclusion Criteria:~* Speech communication barriers.~* Patients with a clear history of allergies to anti-platelet drugs.~* Patients with a clear history of allergies to anti-platelet ᵦ-blockers.~* Patients with a clear history of allergies to statin drugs.~* Patients with a clear history of allergies to antihypertensive drugs.~* Patients with a clear history of allergies to antidiabetic drugs.~* Patients with serious heart failure(better than NYHA class II).~* Patients with cerebral infarction or cerebral hemorrhage.~* Patients with liver dysfunction (AST and ALT\> 2 times that of the reference value).~* Patients with kidney dysfunction (creatinine clearance rate\< 60ml/min).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Smart phone app (Type: EXPERIMENTAL): The app contains education materials for secondary prevention of coronary artery disease. So patients can access them very easily. The app pushes heath management recommendation information on the timeline after percutaneous coronary intervention, and also provides health care lecture to help patients to improve their secondary prevention. And online or telephone consultation ways are integrated into the App to provide convenience for patients to communicate with health care professionals.
- Control group (Type: OTHER): Participants allocated to the control group will receive a booklet with general advice on secondary prevention of coronary artery disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: SNAP VS BIS(OAA/S) Scale During a Sedation Regimen With and Without Ketamine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age : 18-64 years~* ASA : I-III~* Procedure : Breast or gynecological surgery~* Anesthesia :Monitored anesthesia care~Exclusion Criteria:~* Pregnancy~* Breast Feeding~* Body Mass Index \>35kg/m2~* Drug or Alcohol abuse~* Use anticonvulsants~* History of CVA~* Drop-out criteria:~  * Patient or surgeon request~ * Conversion to general anesthesia~ * Inability to obtain data from both monitors

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine Group (Type: ACTIVE_COMPARATOR): ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min.
- No ketamine (Type: NO_INTERVENTION): No ketamine added to anesthesia regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Assessing the Effectiveness of an N-of-1 Platform Using Study of Cognitive Enhancers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* US resident~* 18 years old or over~* Has an iPhone~* Regular caffeine drinker~Exclusion Criteria:~* Pregnant/breastfeeding~* Any contraindication/health issue in which risk is added by consumption of caffeine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Single caffeinated beverage/supplement (Type: ACTIVE_COMPARATOR): None
- Combination caffeine and L-theanine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Detection of Tumor DNA in Blood Samples From Patients With Early Stage Cancer and Healthy Controls

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. For all participants:~* Age 18 years or older~* Able to understand and grant informed consent~* Able to have their blood drawn at enrollment before surgery and 7 to 28 days after surgery~For participants with early stage solid tumors:~* Diagnosed with an early stage (I-III) solid tumor with curative intent surgery without neoadjuvant therapy planned~For healthy control subgroup:~* No prior or current diagnosis of any cancer. Participants with prior in situ cancer or non-melanoma skin cancer will be allowed to participate but will not be included in the healthy control cohort and will be analyzed separately.~Exclusion Criteria:~* Unable to grant informed consent or comply with all study procedures~* Diagnosed with a hematological malignancy (acute or chronic leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, myeloma or lymphoma).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Early stage neoplasm (Type: None): Patients with stage I-III early stage non-hematologic neoplasm
- Healthy Control (Type: None): Patients undergoing surgery for a non-malignant condition with no prior history of malignancy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficiency Evaluation of Photodynamic Therapy With Photofrin® on Unresectable Type III or IV Cholangiocarcinomas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Obtention of a written informed consent.~* Patient over 18.~* Patient with a type III or IV (according to Bismuth classification) histologically proved cholangiocarcinoma ; histologic diagnosis must be proved by biliary brushing, bile cytology, endobiliary biopsy under scope control with pediatric pliers, or by cytologic puncture under scan or echoendscopic control.~* Patient with Karnofsky score ≥ 50 %~* Patient with an efficient initial biliary drainage with prothesis.~* Cancer classified maximum T3N1M1, but only with intrahepatic metastasis occupying less than 25% of hepatic parenchyme (according to TNM cancer classification of extrahepatic biliary ducts' cancers).~* Patient capable of fill in the quality of life questionnaire.~Exclusion Criteria:~* No written informed consent.~* Type I and II cholangiocarcinoma according to Bismuth classification.~* Patients with ASA score 4.~* Patients with clinical and biological signs of biliary infection.~* Patients with a severe visceral disease other than cholangiocarcinoma.~* Patients without an efficient initial biliary drainage.~* Patients with extrahepatic visceral metastasis, except perihilar ganglionic metastasis classified T4N1M+ according to TNM classification.~* Patients whose cholangiocarcinoma has already been resected.~* Patients under or already treated by radiotherapy or chemotherapy treatment for cholangiocarcinoma.~* Patients first treated with metallic prothesis.~* Patients with a contraindication to MRI.~* Patients with porphyria or hypersensibility to porphyrins.~* Patient treated by a non authorized treatment at the time of inclusion.~* Pregnant, parturient or breastfeeding women.~* Non menopaused woman without an efficient contraception.~* Patient under 18.~* Person over 18 under protection according to French Public Health Code.~* Person not affiliated to a social security regimen, or benefiting from such a regimen.~* Person in a exclusion period of another biomedical study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): PDT
- 2 (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MPAACS: Magnesium for the Prevention of Atrial Arrhythmias After Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patient undergoing coronary artery bypass surgery with or without valve procedure~* scheduled for on-pump or cardiopulmonary bypass protocol~Exclusion Criteria:~* existing atrial fibrillation/flutter in the past year or on antiarrhythmic medications~* ventricular fibrillation~* sustained ventricular tachycardia~* 2nd or 3rd degree heart block~* paroxysmal supraventricular tachycardia~* major aortic repair planned during open-heart procedure~* permanent atrial/ventricular pacemaker implanted~* dialysis dependent or creatinine clearance \< 35 umoles/min or oliguric/anuric renal failure~* patient intolerant of beta blockers~* patient has reactive airways disease dependent on regular beta-adrenergic agents~* patient is scheduled to undergo off-pump surgical protocol

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. \>21 years~2. Speak and read English to 5th grade level of higher.~3. Eligible and ready to begin Peg-Interferon and Ribavirin (PEG-IFN/RBV) therapy for HCV at Mount Sinai's Primary Care practice or JMFC~4. HIV infected patients will need to have a CD4 count \> 100 and have demonstrated compliance to retroviral therapy~5. Not majorly depressed upon entry to study.~6. Signed informed consent to participate in CBT study~Exclusion Criteria:~1. Majorly depressed (based on administration of the PHQ-9, score considered for Major Depressive Disorder).~2. Admit to actively abusing illicit drugs or alcohol~3. Medical contraindications to a standard course of interferon/ribavirin therapy (eg: severe anemia, uncontrolled congestive heart failure)~4. Less than one year of life expectancy~5. Current participation in CBT related psychotherapy~6. Participation in any psychotherapy beginning less than 6 months before CBT sessions begin.~7. Initiated anti-depressant medication less than 6 months before CBT sessions begin~8. Severe comorbid psychiatric disease including bipolar disorder, severe personality disorder, or psychotic disorder~9. Active suicidal ideation

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CBT skills based group sessions (Type: EXPERIMENTAL): Cognitive Behavioral Therapy skills based group sessions
- Hepatitis C educational support groups (Type: ACTIVE_COMPARATOR): Hepatitis C educational support groups

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Interpreters as Advocates for Hypertensive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Spanish speaking~* Limited English proficiency~* Uncontrolled hypertension~* Regular visit with primary care provider who is not proficient in Spanish~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Interpreter (Type: EXPERIMENTAL): Professional Spanish interpreter
- Usual Care (Type: NO_INTERVENTION): Usual care provided to patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study of PEAK Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Completed ALO-IIT-012(PEAK study), without major protocol deviations.~* Male, or female, 19 years to 75 years.~* Female with childbearing potential who has a negative urine pregnancy test result at study start and willing to continue practice appropriate birth control during the entire duration of study~* Subjects completed PEAK can be included within 30 days after End Of the Study~* Subjects completed PEAK can be included if their treatment is the same as randomized even after 30 days of End Of the Study.~Exclusion Criteria:~* eGFR(Epidermal growth factor receptor) \< 50mL/min~* AST(aspartate aminotransferase)/ALT(alanine aminotransaminase) \>2.5 upper limit of normal~* Pregnant or lactating women~* Subject who the investigator deems inappropriate to participate in this study~* Patients with a history of bladder cancer or patients with active bladder cancer~* Patients with uninvestigated macroscopic hematuria~* Patients with cardiac failure or a history of cardiac failure (New York Heart Association \[NYHA\] Stages 3 to 4)~* Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption, since this study drug contains lactose

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- alogliptin+pioglitazone (Type: EXPERIMENTAL): A group who treat with alogliptin+pioglitazone: The Combination of Alogliptin 25 mg and pioglitazone 30 mg daily add on metformin for 28 week as extension and followed by 2 years of observation
- alogliptin (Type: ACTIVE_COMPARATOR): A group who treat with alogliptin: Alogliptin 25 mg daily add on metformin for for 28 week as extension and followed by 2 years of observation
- pioglitazone (Type: ACTIVE_COMPARATOR): A group who treat with pioglitazone: Pioglitazone 30 mg daily add on metformin for for 28 week as extension and followed by 2 years of observation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Application of Medical Imaging Procedures in Surgery Implanting in Cancerology With the Aim to Reduce Invasive Acts

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age over 18~* Performance status over 70~* Histological evidence of upper digestive tract cancer~* History of cranial / facial radiotherapy or brachytherapy and/or microvascular fibula transfer.~* Bone volume sufficient to support an implant.~* Mandatory affiliation with a social security system~* Written, voluntary, informed consent~Exclusion Criteria:~* Patient with evolutive malignant disease~* Contraindication to general anesthesia~* Concurrent disease contra-indicating implant surgery (risk of infectious endocarditis, uncontrolled diabetes, HIV, evolutive neoplasia...)~* Patient enrolled in another clinical trial including chemotherapy~* Pregnant or lactating woman~* Anticipation of an impossible follow-up~* Patient deprived of freedom

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues